Alpha Sense BI

MAY 5, 2023

2023 so far has revealed ideal conditions for dealmaking due to valuation resets, lessened competition for deals, and new assets coming to market. Three years later, despite macroeconomic uncertainties, investors remain attracted to this space, particularly the more innovative and tech-influenced sub-sectors like biotech and MedTech.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

APRIL 29, 2024

Below, we explore the trends and themes shaping the venture capital landscape in 2024, and the ways investors can strategically position themselves for success. Competition for fundraising will continue heating up among startup companies in 2024. Forecasting Analysis : Analyze financial data to generate potential forecasts.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

JUNE 6, 2024

In today’s fast-paced and ever-evolving business landscape, staying ahead of the competition is more challenging yet more crucial than ever. Having a dedicated and comprehensive competitor analysis framework is critical, as is the ability to access all the competitive information you need in one place.

Competitor Analysis 40

Competitor Analysis Analysis Battlecard SWOT 40

Alpha Sense BI

APRIL 19, 2024

2023 was all about learning the use cases of genAI, as companies raced to introduce their own genAI offerings and capabilities into a fiercely competitive market (i.e. OpenAI’s ChatGPT ). Having proven to be a catalyst for business growth, genAI is projected to boast a $1.3 Start your free trial today.

Technology 69

Technology Technology Retail Due Diligence 69

Alpha Sense BI

MARCH 28, 2023

Pricing: Learn how the price of Stream by AlphaSense ’s premium expert transcript library can keep you ahead of the competition. Do they have a competitive pricing strategy in place? Try AlphaSense for Free To stay ahead of your competition and be agile in your decision-making, you need expert insights. Who uses expert networks?

Value Chain 52

Value Chain Biotech Research Competitive 52

Evalueserve

DECEMBER 6, 2021

On the other hand, Biotech heavily underperformed post Q1’21 primarily due to the shifting of focus towards cyclicals and negative sentiments arising as of result of greater regulatory clampdown on transformative deals and drug pricing. These companies will be able to reshape the competitive landscape of the pharmaceutical industry.

Capital 98

Capital Globalization Marketing Marketing 98

Sedulo

MARCH 15, 2023

As leaders in competitive strategy consulting, serving the life sciences community for the last 17 years, Sedulo Group can help you: Build a comprehensive view of the current and future competitive landscape. Obtain details on competitor clinical trial locations. Assess and benchmark enrollment timing.

Biotech 52

Biotech Competitive Landscape Pharmaceutical Benchmarking 52